{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:16:36Z","timestamp":1764936996753},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T00:00:00Z","timestamp":1527724800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4523-2","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T12:46:39Z","timestamp":1527770799000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report"],"prefix":"10.1186","volume":"18","author":[{"given":"Lishu","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,31]]},"reference":[{"key":"4523_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/1471-2407-10-529","volume":"10","author":"J Li","year":"2010","unstructured":"Li J, Zhao X, Chen L, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010;10:529.","journal-title":"BMC Cancer"},{"key":"4523_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.6004\/jnccn.2016.0058","volume":"14","author":"V Ravi","year":"2016","unstructured":"Ravi V, Sanford EM, Wang WL, et al. Antitumor response of VEGFR2- and VEGFR3-amplified Angiosarcoma to Pazopanib. J Natl Compr Cancer Netw. 2016;14:499\u2013502.","journal-title":"J Natl Compr Cancer Netw"},{"key":"4523_CR3","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1158\/1078-0432.CCR-11-1987","volume":"18","author":"DR Minor","year":"2012","unstructured":"Minor DR, Kashani-Sabet M, Garrido M, O'Day SJ, Hamid O, Bastian BC. Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res. 2012;18:1457\u201363.","journal-title":"Clin Cancer Res"},{"key":"4523_CR4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/annonc\/mdt484","volume":"25","author":"KN Ganjoo","year":"2014","unstructured":"Ganjoo KN, Villalobos VM, Kamaya A, et al. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol. 2014;25:236\u201340.","journal-title":"Ann Oncol"},{"key":"4523_CR5","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/path.1823","volume":"207","author":"H Joensuu","year":"2005","unstructured":"Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol. 2005;207:224\u201331.","journal-title":"J Pathol"},{"key":"4523_CR6","doi-asserted-by":"publisher","unstructured":"Kristin Kunze, Tilmann Spieker, Ulrike Gamerdinger et al; A Recurrent Activating PLCG1 mutation in cardiac angiosarcomas increases apoptosis resistance and invasiveness of endothelial cells. Published Online First September 24, 2014; DOI: \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1162\n                    \n                  .","DOI":"10.1158\/0008-5472.CAN-14-1162"},{"key":"4523_CR7","doi-asserted-by":"publisher","first-page":"7175","DOI":"10.1158\/0008-5472.CAN-09-2068","volume":"69","author":"CR Antonescu","year":"2009","unstructured":"Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009;69:7175\u20139.","journal-title":"Cancer Res"},{"key":"4523_CR8","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","volume":"27","author":"RG Maki","year":"2009","unstructured":"Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:3133\u201340.","journal-title":"J Clin Oncol"},{"key":"4523_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mds237","volume":"24","author":"M Agulnik","year":"2013","unstructured":"Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24:257\u201363.","journal-title":"Ann Oncol"},{"key":"4523_CR10","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.0.CO;2-P","volume":"86","author":"F Fata","year":"1999","unstructured":"Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86:2034\u20137.","journal-title":"Cancer"},{"key":"4523_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/00130404-200505000-00011","volume":"11","author":"MG Fury","year":"2005","unstructured":"Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005;11:241\u20137.","journal-title":"Cancer J"},{"key":"4523_CR12","unstructured":"Margaret von Mehren, R. Lor Randall and Robert S. Benjamin: Systemic Therapy Agents and Regimens with Activity in Soft Tissue Sarcoma Subtypes. NCCN Clinical Practice Guidelines in Oncology; Soft Tissue Sarcoma. Version 2.2016. SARC-F 1-2 OF 6. Accessed 4 Apr 2016."},{"key":"4523_CR13","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1152\/physrev.00005.2002","volume":"82","author":"L Jussila","year":"2002","unstructured":"Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev. 2002;82:673\u2013700.","journal-title":"Physiol Rev"},{"key":"4523_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/CCO.0b013e32833aaad4","volume":"22","author":"MS Park","year":"2010","unstructured":"Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma\/solitary fibrous tumor. Curr Opin Oncol. 2010;22:351\u20135.","journal-title":"Curr Opin Oncol"},{"key":"4523_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0169-5347(01)02125-5","volume":"16","author":"M Cabeza","year":"2001","unstructured":"Cabeza M, Moilanen A. Design of reserve networks and the persistence of biodiversity. Trends Ecol Evol. 2001;16:242\u20138.","journal-title":"Trends Ecol Evol"},{"key":"4523_CR16","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","volume":"34","author":"J Li","year":"2016","unstructured":"Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase iii trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34:1448\u201354.","journal-title":"J Clin Oncol"},{"key":"4523_CR17","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature04483","volume":"438","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967\u201374.","journal-title":"Nature"},{"key":"4523_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13045-014-0052-x","volume":"7","author":"V Subbiah","year":"2014","unstructured":"Subbiah V, Meric-Bernstam F, Mills GB, et al. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent(R)) a VEGFR2\/PDGFRbeta\/c-kit\/ FLT3\/RET\/CSF1R inhibitor in a phase II trial. J Hematol Oncol. 2014;7:52.","journal-title":"J Hematol Oncol"},{"key":"4523_CR19","doi-asserted-by":"crossref","unstructured":"Shu T, Quan HT, Xie CY. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102:1374\u201380.","DOI":"10.1111\/j.1349-7006.2011.01939.x"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4523-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4523-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4523-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T23:09:56Z","timestamp":1559257796000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4523-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,31]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4523"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4523-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,31]]},"assertion":[{"value":"21 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethical committee of First Affiliated Hospital of Harbin Medical University. Informed written consent was obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of their clinical details and clinical images was obtained from the patient. A copy of the consent form is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"618"}}